ClinicalTrials.gg
RecruitingNCT06359912Updated Apr 11, 2024

Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Critical Limb Ischemia

A Phase 1 interventional study of EPCs and Clinical standard treatment (CST) in Critical Limb Ischemia, sponsored by Allife Medical Science and Technology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-04-11.

Sponsored by Allife Medical Science and Technology Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Chronic Limb-Threatening Ischemia with a site in China — 7 open to participants now, 7 under way, none of them phase 3. Chronic Limb-Threatening Ischemia · China.

Planned enrollment
13th of 15
27 · median 120
Started
2024
with 2 others
Phase 1
3 of 23
1 open now
Registered
17th of 23
by date
Lead sponsor
1 of 23
Allife Medical Science and Technology Co., Ltd.

Among the 23 studies in Chronic Limb-Threatening Ischemia with a site in China, this one is the 13th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2024, is one of 3 in phase 1, and was the 17th registered.

Chronic Limb-Threatening Ischemia

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

7 of the 23 studies in Chronic Limb-Threatening Ischemia with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Chronic Limb-Threatening Ischemia with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to determine if allogeneic Endothelial Progenitor Cells (EPCs) intravenous infusion to a subject with leg ulcer and/or gangrene due to poor blood flow will be safe and if it will relieve leg pain, increase blood flow, and/or cure the leg wound.

Read the detailed description

Critical limb ischemia (CLI) is a progressive disease, which arises as a result of atherosclerosis or vasculitis in leg arteries. Prognosis of CLI is poor, and no effective treatments have been established in patients who are not eligible for the traditional revascularization therapies such as angioplasty and bypass procedures due to the inappropriate anatomy of the leg arteries or frequent reocclusion following revascularization. Therefore, it is necessary to establish novel revascularization treatment to improve prognosis of the no-option patients. The investigators will study the safety and clinical efficiency of vascular regeneration by means of transplantation of allogeneic Endothelial Progenitor Cells in patients with CLI who are not eligible for traditional revascularization treatments. The primary endpoint is the safety and tolerance identified by adverse events related with investigated drug;while the secondary endpoints are evaluation of the preliminary efficacy of EPCs.

03

Conditions studied

  • Critical Limb Ischemia

Keywords

  • Leg Pain
  • Ulcer
  • iscemia
  • Peripheral Vascular Diseases
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • CLI patients fulfilling all the following criteria are considered suitable for inclusion in the study.

    1. Age is between 18 and 80.
    2. Diagnosis of critical limb ischemia, no surgery or interventional therapy, or poor results one month after interventional therapy (no relief of symptoms), Rutherford grade 3, grade 4 or grade 5, while meeting one of the following criteria: 1) severe intermittent claudication; 2) resting pain; 3) ABI≤ 0.60;
    3. Within the last month, Digital Subtraction Angiography (DSA), Computed Tomography Arteriography (CTA), Magnetic Resonance Angiography (MRA),or vascular ultrasound has confirmed that one or more of the arteries (superficial femoral artery, i.e., the femoral artery below the deep femoral artery branch, the popliteal artery, and its following arteries) have a stenosis of ≥70% or occlusion;
    4. The degree of skin ulcer is determined according to Wagner, grade less than or equal to 4;
    5. Resting pain lasted for more than 2 weeks when signing the form
    6. Eligible patients of (both men and women) if sexually active must agree to use a reliable method of with their partners
    7. The subject or agent can understand the basic requirements of the study, provide written informed consent, and follow up according to the trial requirements.

Exclusion criteria

Exclusion Criteria:

  • Any one of the following exclusion criteria is sufficient to disqualify a patient from the study.

    1. Subjects who have received other cell therapies previously
    2. Subjects who have received or are attending any other unlisted clinical study drug or treatment within 4 weeks prior to the first dose;
    3. Stenosis of ≥75% in the main-iliac artery;
    4. Subjects whose Feet or lower limb infections are uncontrollable, or other uncontrolled active infections;
    5. Patients with diabetic proliferating retinopathy (diabetic retinopathy grade 4 according to the International Clinical Classification Standard for diabetic retinopathy)
    6. Acute ischemic disease of the lower limb(s) occurred within the past 2 weeks;
    7. presence of uncontrolled hypertension;
    8. Any one with cerebral infarction, cerebral hemorrhage, heart failure, unstable angina pectoris, acute myocardial infarction, or severe arrhythmia before enrollment;
    9. abnormal Laboratory tests including severe liver, kidney and coagulation disorders, severe anemia etc.
    10. Patients with severe respiratory disease and other active lung infections requiring intervention that were not eligible for participation in the study
    11. surface antigen positive, virus antibody positive, syphilis serum antibody positive or antibody positive
    12. Patients with within the 5 years prior to screening (except for cured basal cell skin carcinoma, cervical carcinoma in situ, papillary thyroid carcinoma)
    13. Patients with mental illness, cognitive impairment, except those cured of depression; estimated survival of less than 12 months
    14. Congenital or acquired immunodeficiency;
    15. Subjects with Pregnant or lactating subjects
    16. Subjects with known allergy to more than 2 drugs
    17. Current or recent history of alcohol or drug abuse
    18. Patients not eligible for enrollment as comprehensively assessed by the investigator
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    Treatment (clinical standard treatment, EPCs)

    Patients receive clinical standard treatment and EPCs IV with a single dose

    Drug: EPCs · Behavioral: Clinical standard treatment (CST)

  • Other
    clinical standard treatment

    Patients receive clinical standard treatment

    Behavioral: Clinical standard treatment (CST)

Interventions

  • DrugEPCs

    IV

    Also known as: iPSC EPCs

  • BehavioralClinical standard treatment (CST)

    Clinical standard treatment

    Also known as: CST

06

What researchers measure

Primary outcomes

  1. adverse events

    Incidence and severity of adverse events assessed by CTCAE V5.0

    Time frame: baseline to 1 year

Secondary outcomes

  1. Painless walking and intermittent claudication distance

    Changes from the baseline of painless walking and intermittent claudication distance by visit

    Time frame: month 6

  2. Blood flow of the affected limb

    Changes from the baseline of Blood flow of the affected limb by visit

    Time frame: month 6

  3. Rutherford grade

    Changes from the baseline of Rutherford grade by visit. The range of Rutherford grade is from 0 (normal) to 6 (worse).

    Time frame: month 6

  4. The area of skin ulcer

    Changes from the baseline of the area of skin ulcer by visit

    Time frame: month 6

  5. Vascular Quality of Life Questionnaire-6 score

    Changes from the baseline of Vascular Quality of Life Questionnaire-6 score by visit. The range of scores is from 6 (normal) to 24.

    Time frame: month 6

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2024; primary completion for Apr 2025, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2024
First posted
Apr 11, 2024
StartEst.
Apr 2024
Primary completionEst.
Apr 2025
CompletionEst.
Jul 2025
Last update
Apr 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06359912
Lead sponsor
Allife Medical Science and Technology Co., Ltd.
Responsible party
Sponsor
First posted
Apr 11, 2024
Start date
Apr 2024 (estimated)
Primary completion
Apr 2025 (estimated)
Completion
Jul 2025 (estimated)
Last update
Apr 11, 2024

Study contacts

Shaoying Lu, Dr
Contact
xjyfyllh@163.com
029-85323473 ext. 029-85323473
Fanggang Li
Contact
lifanggang@allifetech.com
86-18911352611

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion